”the claim will allege that Mesoblast misrepresented the efficacy and potential benefit of treating patients with Remestemcel-L; misrepresented the significance of trial results; did not disclose to the market material information, including the deficiencies in study design and statistics presented.”
Something is not adding up.
In my opinion, this can’t just be left in the market without a response. I think the BoDs need to act like the MSB BoDs for a while (and then when this is over they can go back to whatever it is they were doing before being rudely interrupted).
”the claim will allege that Mesoblast misrepresented the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.035(3.52%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 95.0¢ | $1.461M | 1.499M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 114821 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 36740 | 41 |
View Market Depth
| Last trade - 13.35pm 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |